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In January 2020, a new coronavirus was identified as responsible for a pandemic
acute respiratory syndrome. The virus demonstrated a high infectious capability and
not-neglectable mortality in humans. However, similarly to previous SARS and MERS,
the new disease COVID-19 caused by SARS-CoV-2 seemed to relatively spare
children and younger adults. Some hypotheses have been proposed to explain the
phenomenon, including lower ACE2 expression in children, cross-immunization from
measles/rubella/mumps and BCG-vaccination, as well as the integrity of respiratory
mucosa. Herein, we hypothesize that an additional mechanism might contribute to
children’s relative protection from SARS-CoV-2, the cross-immunization conferred
by previous exposures to other common respiratory coronaviruses. To support our
hypothesis, we show a statistically significant similarity in genomic and protein
sequences, including epitopes for B- and T-cell immunity, of SARS-CoV-2 and the
other beta coronaviruses. Since these coronaviruses are highly diffused across pediatric
populations, cross-reactive immunity might reasonably induce an at least partial
protection from SARS-CoV-2 in children.
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INTRODUCTION
Despite the significant improvements and the efforts made by governments and international
organizations worldwide, the number of COVID-19 cases is still growing, and many issues are still
unsolved, including definition of a standard care, development of effective immunization strategies,
and proper epidemiological framework. Furthermore, the definition of COVID-19 as the cause of
death varies across countries, depending on the role of coexisting conditions that can be differently
accounted. Nonetheless, a different impact on the elderly population, with respect to the pediatric
population that shows a mild disease or an asymptomatic infection has been strikingly reported
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(1, 2). The analysis of SARS-CoV-2 infection incidence and
severity indicates, in particular, two intriguing clinical aspects:
(1) high mean age of infected patients with higher mortality
in patients >65 years old; (2) lowest SARS-CoV-2 incidence
in children with rare cases of severe disease (3). This was also
observed in SARS-CoV and MERS-CoV infection (4, 5). During
SARS-CoV epidemic, the overall mortality was about 15%;
however, the stratified analysis by age, showed <1% mortality in
younger patients (<24 years old) and a mortality rate above 50%
in patients aged above 65 years (6).
By contrast, children have been reported to rarely develop a
severe complication such as Kawasaki disease-like vasculitis (7).
CURRENT HYPOTHESES ASSOCIATED
WITH MORTALITY RATE AND DISEASE
SEVERITY
Although the reasons accounting for the differences in disease
severity and lethality according to age are not yet established, a
few main hypotheses were suggested to explain these differences
between children and adult individuals (8, 9), which might
explain the limited number of severe cases of COVID-19
in children.
In addition to these tentative explanations, some authors
suggested that the low impact of SARS-CoV-2 infection in
children might be correlated with the measles/rubella/mumps
vaccination (10–14). The triple vaccine containing attenuated
strains of measles, mumps, and rubella viruses (MMR) was
introduced about 50 years ago, and it is administered in two doses
at 12–15 months and 4–6 years of age, respectively, even though
a modified schedule could be observed in the different national
health systems. Sequence analyses also showed a suggestive
homology between an important region of S2 fusion protein
of SARS-CoV-2 and the fusion protein F domains in measles
and mumps viruses. Furthermore, a sequence similarity between
the macrodomains with ADP-ribose-1-phosphatase (ADRP)
activity in SARS-CoV-2 non-structural protein 3 (NSP3) and the
rubella virus p150 protein was described. These two sequences
showed 29% amino acid identity with some functional conserved
residues, suggesting that ADRP may play an important role
in the rubella virus and SARS-CoV-2 infections. The rubella
macrodomain has surface-exposed conserved residues and is
included in the attenuated rubella vaccine virus. Interestingly,
the anti-rubella antibodies significantly increase in the severe
COVID-19 cases with respect to mild COVID-19 cases (15).
These amino acid sequence homologies belong to protein regions
that could induce an immunological response in the vaccinated
individuals against these viruses that may then attenuate the
clinical impact of SARS–CoV-2 infection through B- or T-
cell responses.
Another clue of the possible role of vaccinations in the
comprehension of different clinical impact in patients with
SARS-CoV-2 was raised in a study by Miller and coworkers
suggesting a link between Bacillus Calmette–Guerin (BCG)
vaccination and acquired non-specific immunity against SARS-
CoV-2 (16). This study indicates that the countries with specific
and long-standing BCG vaccination showed a reduced morbidity
and mortality with respect to countries without the BCG
vaccination policies.
Although these observations are intriguing and deserve
consideration, they would mention only some factors of this
jigsaw puzzle and do not fully explain why children appear to
be protected against severe SARS-CoV-2 as well as SARS-CoV
and MERS-CoV infections, irrespectively of the geographical
region and the correlated vaccination policy. In our humble
opinion, an additional hypothesis can be raised, certainly
not mutually exclusive with the previous ones. Particularly,
the sequence similarity between Measles Virus F protein and
SARS-CoV-2 S2 protein prompted us to investigate whether a
still higher sequence similarity might exist with other human
Coronavirus proteins.
The human Coronavirus family is composed by seven viruses:
two belonging to alpha coronaviruses (HCoV-NL63 and−229E)
and five to beta coronaviruses (HCoV-OC43, HCoV-HKU1,
SARS-CoV, SARS-CoV-2, MERS-CoV).
HCoV-NL63, HCoV-229E, HCoV-OC43, and HCoV-HKU1
are associated with mild respiratory disease in immune
competent patients with the onset of seasonal epidemics
worldwide. These human coronaviruses are considered the
second major cause of the common cold surpassed only by
Rhinoviruses. In particular, HCoV-OC43 and HCoV-HKU1
induce outbreaks of respiratory diseases especially in temperate
regions, and studies in the USA have demonstrated that HCoV-
OC43 and HCoV-HKU1 infections are mainly observed at the
ages of 1 and 2 years, respectively (17, 18). The infection by
respiratory human Coronaviruses is detectable in the first years
of human life, and the seroconversion of at least one out of four
Coronavirus is detectable in the first two years. Some studies
have shown that 50–75% of the population has antibodies against
either HCoV-OC43 or HCoV-NL63 in the first two years (19–
21). The incidence of infection is higher for HCoV-OC43 and
HCoV-NL63 and, interestingly, early infections due to these
two viruses protect against subsequent infections against HCoV-
HKU1 and HCoV-229E, respectively, whereas the contrary effect
was not observed (20). This indicates a complex immunological
relationship and cross-protection during infections of similar
viruses. In addition, SARS-CoV infection can yield neutralizing
antibodies to HCoV-OC43, and vice versa, HCoV-OC43 is able
to generate cross-reactive antibodies that recognize SARS-CoV
antigens (22, 23).
A study of humoral response against SARS-CoV and MERS-
CoV has demonstrated that the neutralizing antibodies rapidly
declined, and in the ELISA analysis done 2 years later on
the same subjects indicated that the antibody titers were
undetectable or close to background levels (17, 24). Similarly,
the humoral immunological response just declined 1 year after
the infection by HCoV-OC43 and HCoV-HKU1 (20). It is
noteworthy that the seasonal HCoV- can infect the adults,
and the studies have demonstrated that these viruses induce
22–25% of acute respiratory diseases (21, 25). These data
suggest that several HCoV- infections affect the adults who were
exposed to viral infection in the first years of life, even though
the clinical development is characterized by mild symptoms
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TABLE 1 | Identity and similarity score among virus N proteins.
SARS-CoV-2 SARS-CoV HCoV-HKU1 HCoV-OC43 HCoV-NL63 HCoV-229E MERS-CoV
SARS-CoV-2
SARS-CoV 90.5 (97.2)
HCoV-HKU-1 33.3 (64.1) 35.6 (64.2)
HCoV-OC43 34.8 (61.7) 37.4 (63.1) 64.2 (85.0)
HCoV-NL63 34.0 (65.3) 33.0 (64.8) 29.8 (58.9) 33.6 (59.2)
HCoV-229E 28.5 (57.9) 26.9 (58.0) 31.8 (54.4) 30.4 (57.1) 46.6 (71.6)
MERS-CoV 50.0 (75.9) 49.9 (75.3) 33.3 (65.3) 38.1 (65.8) 31.1 (59.6) 28.3 (52.7)
Identity is the amount of identical amino acids between the two proteins; similarity describes the similarity of two protein sequences taking into account the chemical properties of the
amino acids and including gaps. Identity and Similarity scores have been estimated using the FASTA program.
Identity % (similarity %).
TABLE 2 | Identity and similarity score among virus S proteins.
SARS-CoV-2 SARS-CoV HCoV-HKU1 HCoV-OC43 HCoV-NL63 HCoV-229E MERS-CoV
SARS-CoV-2
SARS-CoV 76.0 (91.5)
HCoV-HKU1 29.2 (59.0) 29.3 (59.6)
HCoV-OC43 30.5 (58.2) 30.0 (58.6) 63.3 (84.9)
HCoV-NL63 30.3 (59.8) 29.3 (59.8) 32.8 (63.2) 28.8 (58.3)
HCoV-229E 32.2 (63.0) 28.9 (58.0) 32.5 (62.3) 30.8 (58.4) 64.1 (85.8)
MERS-CoV 31.5 (61.1) 34.1 (63.1) 32.0 (60.8) 31.9 (59.2) 32.3 (59.4) 32.4 (59.6)
See Table 1 for a definition of identity and similarity scores. Identity % (similarity %).
and also asymptomatic infections take place. Therefore, the
respiratory seasonal HCoV- reinfections may be associated
with a subprotective or waning of immunological response
that is not able to neutralize the infection but may minimize
disease aggressiveness.
Overall, the frequent reinfections that occur in children may
suggest that they are less susceptible to severe infections due
to a cross-response to some respiratory coronavirus antigens.
Particularly, beta coronaviruses, such as HCoV-OC43 and
HCoV-HKU1, could show larger homologies with SARS-CoV-2.
These two viruses, remarkably, are supposed to infect at least 70
to 80% of children, being recognized in around 5% of hospitalized
pediatric patients (4).
PROTEIN IDENTITY AMONG HUMAN
CORONAVIRUSES
SARS-CoV-2 is the seventh human coronavirus reported after
HCoV-NL63, HCoV-OC43, HCoV-HKU1, HCoV-229E, SARS-
CoV, and MERS-CoV. The first four respiratory coronaviruses
cause respiratory manifestations, especially in the upper airways,
and do not represent a real clinical problem due to poor
symptomatic outcome, even though in some cases, as in
immunocompromised patients, they can play an important
pathogenic role. However, SARS-CoV and MERS-CoV elicit
more aggressive respiratory disorders, characterized by a
significantly higher complications rate (e.g., pneumonia) and
TABLE 3 | Protein S—aminoacidic identity and similarity scores between human







SARS-CoV 76.0 (91.5) 66.5 (87.7) 90.0 (98.1)
HCoV-HKU1 29.2 (59.0) 21.7 (50.1) 40.3 (73.0)
HCoV-OC43 30.5 (58.2) 22.5 (48.5) 42.5 (72.7)
HCoV-NL63 30.3 (59.8) 25.7(52.0) 33.5 (65.9)
HCoV-229E 32.2 (63.0) 28.2 (56.3) 35.0 (66.5)
MERS-CoV 31.5 (61.1) 23.6 (53.0) 44.2 (74.0)
Scores were calculated on the entire protein length (YP_009724390.1) or on the subregion
S1 (P0DTC2 pos: 13-685) or S2 (P0DTC2 pos: 686-1237). Each number indicates identity
percentage followed by similarity percentage in parenthesis. Identity and similarity score
have been defined in Table 1.
mortality. However, their spread in the populations has been
definitely less wide, especially as far as MERS-CoV is concerned.
Alignment of virus proteins or target fragment of the virus
proteins was accomplished using either FASTA (version 36.3.8g,
https://faculty.virginia.edu/wrpearson/fasta/fasta36/) or BLAST
(version 2.11.0; https://ftp.ncbi.nlm.nih.gov/blast/executables/
blast+/LATEST/) softwares. Both FASTA and BLAST programs
have the same goal: to identify statistically significant sequence
similarity that can be used to infer homology. The homology
results rely on two different scores: E-value and bit score. The
expected (E) value is a parameter that describes the number of
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Identity (%) Mapped start Mapped end E-value BIT-score
HCoV-HKU1 S_747-763 46.6 829 843 6.97e-04 21.6
S_747-763 77.7 603 611 0.054 16.2
S_936-952 52.9 1,021 1,037 0.001 20.8
S_1101-1115 40.0 1,187 1,201 0.002 20.0
HCoV-OC43 S_747-763 46.6 827 841 7.30e-04 21.6
S_936-952 47.0 1,020 1,036 0.018 17.3
HCoV-229E S_304-321 53.8 40 52 0.026 16.9
S_747-763 41.6 542 553 0.052 16.2
S_936-952 56.2 822 837 5.64e-04 21.6
S_996-1004 77.7 881 889 0.006 17.7
S_1192-1200 55.5 1,094 1,102 0.015 16.5
HCoV-NL63 S_747-763 50.0 799 814 0.004 19.6
S_936-952 41.1 1,002 1,018 0.009 18.5
S_996-1004 77.7 1,062 1,070 0.007 17.7
S_1101-1115 41.6 152 163 0.046 16.2
MERS-CoV S_304-321 44.4 352 369 4.41e-04 21.9
S_747-763 43.7 816 831 3.05e-04 22.3
S_1192-1200 87.5 1,276 1,283 0.008 17.7
S_1220-1228 75.0 1,303 1,310 0.007 17.7
Homology values are considered significant when showing an E-value <0.05, or since the database is composed of a small number of short fragments (SARS-CoV-2 derived cell
epitopes) when showing an arbitrarily bit-score ≥14. The table shows the homologies identified with an E-value <0.10.








Mapped end E-value BIT-score
HCoV-HKU1 N_138-146 80.0 421 425 0.046 14.6
HCoV-OC43 N_138-146 66.6 155 160 0.093 13.9
HCoV-229E N_138-146 57.1 325 331 0.087 13.9
N_265-274 83.3 260 265 0.044 14.6
HCoV-NL63 - - - - - -
MERS-CoV N_265-274 60.0 257 266 0.002 18.1
Homology values are considered significant when showing an E-value <0.05, or since the database is composed of a small number of short fragments (SARS-CoV-2 derived cell
epitopes) when showing an arbitrarily bit-score ≥14. The table shows the homologies identified with an E-value <0.10.
hits one can “expect” to see by chance when searching a database
of a particular size. High E values have a higher probability of
occurring in the database purely by chance. The bit score is a
normalized raw score to the statistical parameters of the scoring
system (i.e., length of query and library sequences) and allows for
alignment comparisons between independent searches.
It is interesting to note that SARS-CoV and SARS-CoV-
2 have a high identity degree of their genomic sequences
(with about 90% sequence identity). Since SARS-CoV, SARS-
CoV-2, MERS CoV, HCoV-OC43, and HCoV-HKU1 are beta
coronaviruses, we aimed to study the amino acid alignment of
proteins such as S and N, which are structural proteins with
high homology in all coronaviruses, with relevant immunogenic
properties (i.e., contain strong epitopes for B and T cells) in
SARS-CoV-2 (26). SARS-CoV-2 showed higher identity for N
and S aminoacidic sequences with SARS-CoV (90.5 and 76%,
respectively), whereas the identity with other beta coronaviruses
was around the 30% for N and S, with the exception of N
protein that had an identity of 50% with MERS-CoV N protein
(Tables 1, 2). It is noteworthy that the analysis of aminoacidic
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Identity (%) Mapped start Mapped end E-value BIT-score
HCoV-HKU1 S_287-317 40.0 278 307 2.81e-05 26.6
S_524-598 25.3 611 681 1.61e-05 29.3
S_888-909 50.0 977 994 3.62e-05 25.4
HCoV-OC43 S_287-317 42.8 286 313 4.84e-06 28.5
S_524-598 28.1 611 681 1.09e-06 32.7
S_888-909 44.4 976 993 1.69e-04 23.5
HCoV-229E S_524-598 27.6 434 497 9.22e-05 26.9
S_888-909 36.8 760 778 0.002 20.8
HCoV-NL63 S_524-598 36.1 613 648 4.99e-06 30.8
S_802-819 50.0 1,224 1,235 0.054 16.2
S_888-909 36.8 941 959 0.004 19.6
MERS-CoV S_287-317 43.3 336 365 3.27e-08 34.7
S_524-598 29.0 603 633 0.048 19.6
S_888-909 42.8 963 983 1.56e-04 23.9
Homology values are considered significant when showing an E-value <0.05, or since the database is composed of a small number of short fragments (SARS-CoV-2 derived cell
epitopes) when showing an arbitrarily bit-score ≥16. The table shows the homologies identified with an E-value <0.10.






Identity (%) Mapped start Mapped end E-value BIT-score
HCoV-HKU1 N_42-62 45.0 54 73 0.003 18.9
N_153-172 52.9 170 186 5.61e-05 23.5
N_153-172 71.4 54 60 0.013 16.9
HCoV-OC43 N_42-62 57.1 64 77 0.003 18.5
N_153-172 45.0 168 187 2.83e-05 24.3
HCoV-229E - - - - - -
HCoV-NL63 - - - - - -
MERS-CoV N_42-62 70.0 33 52 2.31e-09 35.8
N_153-172 55.0 142 161 6.16e-06 26.2
N_355-401 34.1 353 393 0.004 20.0
Homology values are considered significant when showing an E-value <0.05, or since the database is composed of a small number of short fragments (SARS-CoV-2-derived cell
epitopes) when showing an arbitrarily bit-score ≥14. The table shows the homologies identified with an E-value <0.10.
identity of S2 subregion of S protein has demonstrated that
the SARS-CoV-2 has strong similarity values with SARS-CoV
(90%), MERS-CoV (44.2%), HCoV-OC43 (42.5%), and HCoV-
HKU1 (40.3%) (Table 3). On the other hand, the aminoacidic
identity on S1 subregion is lower; in fact, the identity with
SARS-CoV, MERS-CoV, HCoV-OC43, and HCoV-HKU1 are
66.5, 23.6, 22.5, and 21.7%, respectively. These data suggest
that S2 is the subregion more conserved among the different
human Coronaviruses, and its importance in the fusion step
of viral infection indicates this protein as a valuable target for
immune response.
We then sought to analyze the SARS-CoV-2-derived T- and
B-cell epitopes of either protein N or S as defined by Grifoni et al.
(27). Remarkably, we recognized a statistically significant degree
of identity in the human beta coronaviruses and partially in alpha
coronaviruses as shown in Tables 4–7.
This homology could be consistent with the formation of some
antibodies directed against respiratory coronaviruses, which can
protect, albeit partially, against SARS-COV-2. Since Coronavirus
infection usually occurs in the early years of life and the immune
response fromCoronavirus is not maintained for a long time, this
could explain the resistance of children and not in the elderly.
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TABLE 8 | Protein S—aminoacidic identity and similarity between SARS-CoV-2S
protein (YP_009724390.1) and its subregions S1 (P0DTC2 13-685) and S2
(P0DTC2 686-1237) [identity % (similarity %)] with measles virus F1 protein,


















22.5 (50.0) 24.3 (51.4) 22.5 (50.0)
In this light, based on genetic identities across coronaviruses,
the establishment of specific immunity against one of the four
common strains might partially protect against from the other
ones, including SARS-CoV, MERS-CoV, and SARS-CoV-2. This
would easily explain why only few children are symptomatic,
why the disease course is overall milder in this category, and
why asymptomatic carriers have been frequently observed among
children (28–31).
In addition, we have seen how conserved sequences can
be present in putative epitopes for B- and T-cells (27).
The same procedure was used for the N protein, as shown
in Table 4. Several putative epitopes of SARS-CoV-2 are
conserved in HCoV-OC43 and HCoV-HKU1, thus reinforcing
the possibility of cross-reaction. Interestingly, some reports
indicated a correlation between HCoV-OC43 and SARS-CoV-
2 for T-antigens (27, 32, 33). These observations sustain the
hypothesis that early infections by beta coronaviruses may induce
a cross-reactive immune response and influence the development
of disease using both B- and T-cell response.
Of note, we have aligned (Table 8) SARS-CoV-2 S1 and S2
amino acid sequences with measles virus F1 protein, as recently
emphasized, mumps virus F1 protein, and rubella virus E1
protein. In all cases, we demonstrated a lower identity than
for human respiratory coronaviruses was observed (Table 8 and
Supplementary Table 1).
DISCUSSION
The set of these observations leads us to define how it is possible
that infections by coronaviruses, such as HCoV-OC43, could lead
to an immune response that allows or, more precisely, contributes
to the child having pathology in the worst mild scenario. The
respiratory Coronavirus infection and the vaccination against
rubella/mumps/measles could put children in optimal conditions
for a prompter immunological defense against SARS-CoV-2. In
particular, IgA might play a significant protective role as shown
in SARS-CoV and MERS-CoV infections (34, 35).
When compared to its SARS-CoV and MERS-CoV, SARS-
CoV-2 seems to have greater infectivity (higher R0) but less
lethality. It has many similarities to the SARS-CoV virus,
which in 2003 killed 774 people and infected more than 8,000,
with very similar symptoms: fever, cough, headache, breathing
difficulties, and pneumonia. Even for SARS-CoV, there were
few cases among children: only 80 cases confirmed in the
laboratory and 55 probable or suspect cases. In a 2007 report,
it is documented that children under 12 had milder SARS-
CoV-related symptoms than adults. Relatively few children or
teenagers died from this Coronavirus. Similarly, during the
MERS outbreak in 2016, it was reported that the virus was rare
in children, although the “reason for the low prevalence was not
known (36).”
CONCLUSION
In conclusion, we hypothesize that previous infections from
other beta coronaviruses may confer partial protection from
SARS-CoV-2 through some degrees of cross-immunity,
especially in pediatric patients. Hence, the onset of cross-
reactivity among the different beta coronaviruses may play
an important role in the attenuation of disease severity
and then clinical impact on children. This cross-immunity,
comprising both T- and B-cell compartments, may be
possibly increased by vaccination with measles/mumps/rubella
vaccination through an important homology of some rubella
and paramyxovirus proteins with respect to SARS-CoV-
2 S protein. To fully understand the complex mechanisms
underlying the relative resistance to SARS-CoV-2 observed
in children, it is now warranted to perform functional as
well as epidemiological studies incorporating serology for the
commonest beta coronaviruses.
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